Cardiol Therapeutics (CRDL) Share-based Compensation (2020 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Share-based Compensation came in at $1.3 million in Q1 2026, up 68.11% YoY from $799345.1 in Q1 2025, and down 37.83% on a QoQ basis from $2.2 million in Q4 2025.
Cardiol Therapeutics (CRDL) Share-based Compensation (2020 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 7 years of Share-based Compensation data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 68.11% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 21.83% YoY) and the FY2025 annual result came in at $7.7 million, down 24.92% from the prior year.
- Share-based Compensation fell to $1.3 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.2 million in Q3 2024 to a low of -$456672.1 in Q2 2022.
- A 5-year average of $1.6 million and a median of $1.3 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 167.91% — and 2024, when it jumped 303.6%.
- Tracing CRDL's Share-based Compensation over 5 years: stood at $698362.7 in 2022, then grew by 6.52% to $743899.4 in 2023, then jumped by 202.86% to $2.3 million in 2024, then declined by 4.07% to $2.2 million in 2025, then plunged by 37.83% to $1.3 million in 2026.
- The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Cardiol Therapeutics | 215.50 Mn | 196.65 Mn | - | 1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.34 Mn |
| Mar 31, 2026 | 1.34 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 799,345.08 |
| Mar 31, 2025 | 799,345.08 |
| Dec 31, 2024 | 2.25 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 669,460.32 |
| Mar 31, 2024 | 669,460.32 |
| Dec 31, 2023 | 743,899.39 |
| Dec 31, 2023 | 743,899.39 |